MaxCyte, Inc. (MXCT): Price and Financial Metrics
MXCT Price/Volume Stats
| Current price | $5.10 | 52-week high | $5.32 |
| Prev. close | $4.94 | 52-week low | $3.16 |
| Day low | $4.95 | Volume | 895,900 |
| Day high | $5.20 | Avg. volume | 691,867 |
| 50-day MA | $4.00 | Dividend yield | N/A |
| 200-day MA | $4.13 | Market Cap | 539.13M |
MXCT Stock Price Chart Interactive Chart >
MaxCyte, Inc. (MXCT) Company Bio
MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
MXCT Price Returns
| 1-mo | 25.62% |
| 3-mo | 34.21% |
| 6-mo | 6.47% |
| 1-year | -0.20% |
| 3-year | -22.61% |
| 5-year | N/A |
| YTD | 22.60% |
| 2024 | -11.49% |
| 2023 | -13.92% |
| 2022 | -46.42% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...